Bessemer Group’s Ascendis Pharma A/S ASND Stock Holding History

Bessemer Group’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$12K	Buy	44 +14	+47%	+$3.27K	﹤0.01%	2111
2026 Q1	$7K	Buy	30 +12	+67%	+$2.69K	﹤0.01%	2170
2025 Q4	$4K	Buy	+18	New	+$3.72K	﹤0.01%	2277
2024 Q4	–	Sell	-733	Closed	-$109K	–	2461
2024 Q3	$109K	Buy	733 +102	+16%	+$13.8K	﹤0.01%	1269
2024 Q2	$86K	Sell	631 -245	-28%	-$33.3K	﹤0.01%	1200
2024 Q1	$132K	Buy	876 +332	+61%	+$47.4K	﹤0.01%	1117
2023 Q4	$69K	Hold	544	–	–	﹤0.01%	1279
2023 Q3	$51K	Hold	544	–	–	﹤0.01%	1339
2023 Q2	$49K	Hold	544	–	–	﹤0.01%	1380
2023 Q1	$58K	Buy	+544	New	+$62.2K	﹤0.01%	1189
2022 Q2	–	Sell	-78	Closed	-$9K	–	1870
2022 Q1	$9K	Hold	78	–	–	﹤0.01%	1397
2021 Q4	$10K	Hold	78	–	–	﹤0.01%	1414
2021 Q3	$12K	Hold	78	–	–	﹤0.01%	1324
2021 Q2	$10K	Hold	78	–	–	﹤0.01%	1339
2021 Q1	$10K	Buy	+78	New	+$11.9K	﹤0.01%	1298

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Bessemer Group's ASND Position: Q2 2026 in Review

Bessemer Group increased its Ascendis Pharma A/S (ASND) stake by 47% in Q2 2026, buying an estimated $3.27K and bringing the position to 44 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #2111.

Bessemer Group first reported a position in ASND in Q1 2021 and has held it in 15 quarters since. The position peaked at $132K in Q1 2024. 312 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Bessemer Group held 44 shares of Ascendis Pharma A/S worth $12K as of Q2 2026.
Bessemer Group bought 14 Ascendis Pharma A/S shares in Q2 2026, an estimated $3.27K.
Ascendis Pharma A/S made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2111 holding.
Bessemer Group first reported a position in Ascendis Pharma A/S in Q1 2021 and has held it in 15 quarters since.
Bessemer Group's Ascendis Pharma A/S position peaked at $132K in Q1 2024.
312 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.